U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H26N4O23P4
Molecular Weight 790.3079
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIQUAFOSOL

SMILES

c1cn([C@@]2([H])[C@@]([H])([C@@]([H])([C@@]([H])(COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@]3([H])[C@]([H])([C@]([H])([C@]([H])(n4ccc(nc4=O)O)O3)O)O)O2)O)O)c(=O)nc1O

InChI

InChIKey=NMLMACJWHPHKGR-NCOIDOBVSA-N
InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H26N4O23P4
Molecular Weight 790.3079
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/

Diquafosol, a dinucleotide Up4U, is an agonist for purinergic P2Y2 receptor. Diquafosol stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. The Japanese Ministry of Health, Labour and Welfare granted approval for DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) for the treatment of dry eye.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.1 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIQUAS

Approved Use

DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium) should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality.

Launch Date

1.27128961E12
PubMed

PubMed

TitleDatePubMed
The medicinal chemistry of the P2 receptor family.
2001
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
2001 Aug
Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
2001 Jan
Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits.
2002
Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells.
2002
INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model.
2002 Aug
Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.
2002 Dec 5
P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.
2002 May
Novel noninvasive sensitive determination of tear volume changes in normal cats.
2002 Nov-Dec
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.
2002 Sep
Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits.
2003 Feb
Diquafosol tetrasodium. Inspire/Allergan/Santen.
2003 Nov
Molecule of the month. Diquafosol tetrasodium.
2003 Oct
Diquafosol tetrasodium: a novel dry eye therapy.
2004 Jan
Recent advances in the management of ocular complications of Sjögren's syndrome.
2005 Jul
P2 receptors activated by uracil nucleotides--an update.
2006
New approaches in Sjögren's syndrome therapy.
2007 Mar
[A molecular marker for dry eye].
2007 Mar
Therapeutic targets in dry eye syndrome.
2008 Apr
Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.
2008 Aug
Preliminary effects of oral uridine on the ocular surface in dry eye patients.
2009 Aug
Patents

Sample Use Guides

DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium). Usually, instill 1 drop a time 6 times daily.
Route of Administration: Topical
3% diquafosol tetrasodium had a significant, time-dependent, inhibitory effect on human corneal epithelial cells (HCEC) proliferation and cytotoxicity. HCECs treated with diquafosol detached more from the bottoms of dishes and damaged cells showed degenerative changes, such as, reduced numbers of microvilli, vacuole formation, and chromatin of the nuclear remnant condensed along the nuclear periphery.
Substance Class Chemical
Created
by admin
on Sat Jun 26 07:18:17 UTC 2021
Edited
by admin
on Sat Jun 26 07:18:17 UTC 2021
Record UNII
7828VC80FJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIQUAFOSOL
INN   MI   WHO-DD  
INN  
Official Name English
P1,P4-DI(URIDINE 5'-TETRAPHOSPHATE), TETRASODIUM SALT
Common Name English
URIDINE, 5'-(PENTAHYDROGEN TETRAPHOSPHATE), P'''->5'-ESTER WITH URIDINE
Common Name English
DIQUAFOSOL [MI]
Common Name English
DIQUAFOSOL [INN]
Common Name English
DIQUAFOSOL [WHO-DD]
Common Name English
P1, P4-DI(URIDINE 5'-TETRAPHOSPHATE), TETRASODIUM SALT
Common Name English
URIDINE(5')TETRAPHOSPHO(5')URIDINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78283
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
Code System Code Type Description
MESH
C403315
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
CAS
59985-21-6
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
EVMPD
SUB87041
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
ChEMBL
CHEMBL221326
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
FDA UNII
7828VC80FJ
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
DRUG CENTRAL
4900
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
PUBCHEM
148197
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
MERCK INDEX
M4661
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY Merck Index
INN
8326
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
NCI_THESAURUS
C65436
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
EPA CompTox
59985-21-6
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
WIKIPEDIA
DIQUAFOSOL
Created by admin on Sat Jun 26 07:18:17 UTC 2021 , Edited by admin on Sat Jun 26 07:18:17 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY